PENTASA 1 G — DIN 02399466
MESALAZINE : 1 G · FERRING INC · TABLET (EXTENDED-RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is PENTASA?
PENTASA 1 G contains MESALAZINE : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02399466, held by FERRING INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 12-Mar-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PENTASA used for?
Treatment and maintenance of mild to moderate active ulcerative colitis; management and maintenance of mild to moderate Crohn’s Disease; treatment of acute ulcerative proctitis (suppositories).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Mesalazine cost around the world?
Mesalazine is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 8 | 48 | AUD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 19 | 25 | EUR███.██ |
| Greece | producer price (ex-factory) | 21 | 21 | EUR███.██ |
| Saudi Arabia | public | 16 | 21 | SAR███.██ |
| Czechia | max producer price (ex-factory) | 6 | 17 | CZK███.██ |
| South Africa | single exit price | 16 | 17 | ZAR███.██ |
| United Arab Emirates | public | 15 | 16 | AED███.██ |
| Luxembourg | reimbursement | 16 | 16 | EUR███.██ |
| Bahrain | retail (max) | 4 | 9 | BHD███.██ |
| United Kingdom | hospital | 5 | 5 | GBP███.██ |
| Morocco | PPV (public price) | 1 | 3 | MAD███.██ |
198 pack listings across 127 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Mesalazine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Mesalazine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
11 holders have a Canadian DIN containing Mesalazine, across 29 DINs, of which 18 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FERRING INC | 7 | 5 | PENTASA, PENTASA ENEMA 2G/100ML, PENTASA EXTENDED-RELEASE TABLETS 250MG | Sourceable in Canada |
| ABBVIE CORPORATION | 5 | 5 | SALOFALK | Sourceable in Canada |
| AVIR PHARMA INC. | 4 | 4 | MEZERA | Sourceable in Canada |
| TILLOTTS PHARMA AG | 3 | 2 | MESALAMINE, OCTASA | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 1 | NTP-5-AMINOSALICYLIC ACID, TEVA-5 ASA | Sourceable in Canada |
| TAKEDA CANADA INC | 1 | 1 | MEZAVANT | Sourceable in Canada |
| ALLERGAN INC | 2 | 0 | ASACOL, ASACOL 800 | No marketed DIN |
| AXCAN PHARMA INC | 2 | 0 | SALOFALK (R) 5-ASA ENTERIC COATED TAB- 250MG, SALOFALK (R) 5-ASA SUPPOSITORIES - 250MG | No marketed DIN |
| GLAXOSMITHKLINE INC | 1 | 0 | MESASAL | No marketed DIN |
| PENDOPHARM DIVISION OF PHARMASCIENCE INC | 1 | 0 | PENDO-5 ASA | No marketed DIN |
| SANIS HEALTH INC | 1 | 0 | 5-ASA | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 G |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | Tablets: Blister strips of 10. Enemas: Carton of 7 bottles with hygienic bags. Suppositories: Blister cards of 5 or 7, cartons of 28 or 30 with finger protectors. |
| Storage | Not explicitly detailed in the provided text (Section 11 referenced but content not visible), though general stability is implied. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Mesalazine |
|---|---|
| ATC code | A07EC02 |
| AHFS class | 56:36.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02399466 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2399466 |
| Brand name | PENTASA |
| Generic / active ingredient | MESALAZINE : 1 G |
| Market authorization holder | FERRING INC |
| Health Canada schedule | Prescription |
| ATC code | A07EC02 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A07EC |
| Current status | MARKETED |
| Status date | 12-Mar-2013 |
| Original market date | 2013-03-12 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Tablets: 2-4 g daily. Enema: 1-4 g daily at bedtime. Suppository: 1 g daily at bedtime. Tablets should be swallowed whole with meals. Prolonged retention of rectal forms is recommended.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Gastric or duodenal ulcer; urinary tract obstruction, renal parenchymal disease or severe renal impairment; hypersensitivity to salicylates; severe hepatic impairment; infants under 2 years.
Warnings and precautions
Risk of severe cutaneous adverse reactions (SCARs), nephrotoxicity, acute intolerance syndrome, and cardiac hypersensitivity (myocarditis/pericarditis). Monitor blood counts and renal function.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
18 of 29 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MEZAVANT | 1.2 G | TABLET (DELAYED AND EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | 02297558 |
| MEZERA | 500 MG | TABLET (DELAYED-RELEASE) | AVIR PHARMA INC. | MARKETED | 02524481 |
| MEZERA | 1 G | TABLET (DELAYED-RELEASE) | AVIR PHARMA INC. | MARKETED | 02545012 |
| MEZERA | 1 G | FOAM | AVIR PHARMA INC. | MARKETED | 02474026 |
| MEZERA | 1 G | SUPPOSITORY | AVIR PHARMA INC. | MARKETED | 02474018 |
| OCTASA | 1600 MG | TABLET (DELAYED-RELEASE) | TILLOTTS PHARMA AG | MARKETED | 02529610 |
| OCTASA | 800 MG | TABLET (DELAYED-RELEASE) | TILLOTTS PHARMA AG | MARKETED | 02465752 |
| PENTASA | 1 G / 100 ML | SUSPENSION | FERRING INC | MARKETED | 02153521 |
| PENTASA | 1 G | SUPPOSITORY | FERRING INC | MARKETED | 02153564 |
| PENTASA | 4 G / 100 ML | SUSPENSION | FERRING INC | MARKETED | 02153556 |
2 · Same class — other molecules in ATC A07EC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Mesalazine | 5-ASA · ASACOL · ASACOL 800 · MESALAMINE · MESASAL · MEZAVANT · MEZERA · NTP-5-AMINOSALICYLIC ACID · OCTASA · PENDO-5 ASA · PENTASA · PENTASA ENEMA 2G/100ML · PENTASA EXTENDED-RELEASE TABLETS 250MG · SALOFALK · SALOFALK (R) 5-ASA ENTERIC COATED TAB- 250MG · SALOFALK (R) 5-ASA SUPPOSITORIES - 250MG · TEVA-5 ASA | 29 | 18 | Yes |
| Sulfasalazine | APO SULFASALAZINE TAB 500MG · JAMP SULFASALAZINE · ORB-SULFASALAZINE EC · PMS-SULFASALAZINE 500MG/TAB USP · PMS-SULFASALAZINE-E.C. TAB 500MG · RATIO-SULFASALAZINE EN · RATIO-SULFASALAZINE TAB 500MG · S.A.S. ENTERIC 500MG · SALAZOPYRIN EN-TABS 500 MG · SALAZOPYRIN ENEMA 3.0GM/100ML · SALAZOPYRIN ENEMA 3GM/100ML · SALAZOPYRIN TAB 500MG · SAS ENEMA 3GM/100ML · SAS TAB 500MG | 14 | 5 | Yes |
| Olsalazine | DIPENTUM | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A07E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A07EA | Betamethasone · Budesonide · Hydrocortisone · Tixocortol | 16 | 6 |
| A07EB | Cromoglicic Acid | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PENTASA called?
The same molecule, Mesalazine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Salofalk | Latin | Australia, Czechia, Saudi Arabia |
| Asacol | Latin | Australia, Bahrain, Czechia, Saudi Arabia |
| Asacol Enema | Latin | Bahrain, Czechia, South Africa |
| Mezavant | Latin | Australia, South Africa |
| ASACOL™ | Latin | United Arab Emirates |
| MESALZ | Latin | Australia |
| Mesasal | Latin | Australia |
| MEZTAS | Latin | Australia |
| PENTASA PROLONG | Latin | Czechia |
| PENTASA SACHET | Latin | Czechia |
| Asacol Suppositories | Latin | South Africa |
| Asacol Tablets | Latin | South Africa |
| COLIZEM | Latin | South Africa |
| Pentasa Klysma | Latin | Austria |
| PENTASA XTEND | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.